DEFINITIVE CONTRACT
Active75N93026C00012
Department of Health and Human Services › National Institutes of Health › NATIONAL INSTITUTES OF HEALTH NIAID
$2.9M
obligated · signed 2 months ago
TO DEVELOP A THERAPEUTIC SMALL MOLECULE VIRAL ENTRY INHIBITOR AS A MEDICAL COUNTERMEASURE FOR FILOVIRUS INFECTION.
Performance timeline
Start
Aug 3, 2026
End
Jun 30, 2027
with all options
Loading status
This contract is likely in the recompete window
Ends with all options: Jun 30, 2027
ARISAN THERAPEUTICS INC
Contract 75N93026C00012
UEI
PYRKTQPNVJZ8
Parent Company
ARISAN THERAPEUTICS INC
Capabilities & Certifications
Headquarters Location
Congressional District: 49
Current Obligation
$2,933,547
Base + Exercised Options
$2,933,547
Total Ceiling Value
$23,878,987
Contract Type
COST PLUS FIXED FEE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Place of Performance
Congressional District: 49
Awarding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH NIAID
Office
Funding Agency
Top-tier agency
National Institutes of Health
Sub-tier agency
NATIONAL INSTITUTES OF HEALTH NIAID
Office
Solicitation procedures, competition exceptions, labor standards and account totals.